norUrsodeoxycholic acid

Phase 3Small molecule

norUrsodeoxycholic acid is one of 4 small molecule programs targeting Primary Sclerosing Cholangitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Sclerosing CholangitisActive, not recruiting

Primary Sclerosing CholangitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Primary Sclerosing Cholangitis

#DrugCompanyPhaseTrials

Iqirvo

Ipsen

Phase 3

2 2

Tricor

JJagotec

Phase 2

1 3

norUrsodeoxycholic acid

DDr. Falk Pharma GmbH

Phase 3

2 4

Volixibat

MMirum Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

NASH1 trial

Norursodeoxycholic Acid vs. Placebo in NASH

Unknown status·—·Phase 2·NCT05083390·363 enrolled

Unspecified1 trial

norUrsodeoxycholic Acid vs Placebo in PSC

Active, not recruiting·—·Phase 3·NCT03872921·303 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for norUrsodeoxycholic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — norUrsodeoxycholic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for norUrsodeoxycholic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr. Falk Pharma GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDr. Falk Pharma GmbH

norUrsodeoxycholic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

NASH1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News